Syntegon reports a record year for 2025 with a 10 percent increase in revenue. The pharmaceutical business in particular contributed to the success with a plus of 22 percent.
The global market for pharmaceutical packaging is growing steadily, and Syntegon has benefited significantly from this development in 2025. With a revenue increase of 10 percent to 1.75 billion euros and an order intake of 1.86 billion euros, the company recorded a record year. Growth in the pharmaceutical sector was particularly noteworthy, contributing 22 percent to overall success.
Strong results and strategic investments
Syntegon was able to increase its EBITDA margin to 16.1 percent, an increase of 210 basis points. This improvement was the result of consistent cost discipline, optimised project execution and the realignment of the global production network. Furthermore, the company invested in expanding its capacities and innovations, including the opening of a new pharmaceutical solids production facility in Fellbach and the introduction of the gloveless, high-speed filling line SynTiso. This innovation sets new standards for preventing contamination risks in pharmaceutical production.
Growth in the pharmaceutical sector
Syntegon's pharmaceutical sector benefited from the increasing demand for biologics and injectable therapies. Stricter regulatory requirements led to increased demand for technologically sophisticated solutions, it states. The acquisition of Telstar expanded Syntegon's portfolio of end-to-end solutions in the pharmaceutical sector and already contributed to revenue growth in the first year.
Outlook for 2026
With a strong market position and a broad customer base, Syntegon is well-positioned for further growth. The company aims to increase its market share in stable end markets and plans to expand more strongly in the USA. The 2030 business plan envisages strengthening its innovation leadership and scaling the service business.
Source: Syntegon
